Tommy Li is an accomplished professional in clinical pharmacology and quantitative science, currently serving as the Director at Genmab since August 2019, following roles as Associate Director and Principal Scientist within the same department. Prior experience includes a tenure at Merck as a Senior Scientist, where responsibilities encompassed representing oncology clinical pharmacology on immuno-oncology programs and leading modeling and simulation efforts. An early internship experience at The Janssen Pharmaceutical Companies of Johnson & Johnson involved implementing novel exposure-response analyses for clinical endpoints. Tommy Li holds a Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences from the University at Buffalo and a Bachelor of Science in Chemical and Biomedical Engineering from Carnegie Mellon University.